A High-Coverage Epitope-Based Vaccine Design for EIAV Envelope Polyprotein Using an Immunoinformatic Approach

Area of Science:

• Veterinary Virology
• Immunoinformatics
• Vaccine Development

Background:

• Equine Infectious Anemia (EIA) is a significant retroviral disease affecting equids worldwide.
• Current vaccines lack optimal efficacy against prevalent American EIA virus strains.
• There is a critical need for a broadly protective EIA vaccine for American horse populations.

Purpose of the Study:

• To identify potential epitope regions on EIA virus surface proteins (gp90 and gp45).
• To design a novel chimeric envelope protein as a vaccine candidate.
• To evaluate the in silico immunogenic and safety profile of the designed vaccine candidate.

Main Methods:

• Utilized state-of-the-art bioinformatics tools to analyze EIA virus surface proteins.
• Selected conserved epitope regions with high coverage across American EIAV strains.
• Constructed a chimeric envelope protein by fusing selected epitope regions.
• Performed in silico analysis of physicochemical, immunogenic, allergenic, and toxic properties.
• Predicted protein structure and validated its stability.
• Assessed potential for cytotoxic immune responses via molecular docking to ELA alleles.

Main Results:

• Identified eight conserved epitope regions on gp90 and gp45 surface proteins.
• Designed a novel chimeric envelope protein vaccine candidate.
• In silico analyses predicted high immunogenicity and favorable safety profile (low allergenicity/toxicity).
• Predicted protein structure was validated.
• Molecular docking suggested potential for triggering cytotoxic immune responses.

Conclusions:

• The designed chimeric envelope protein represents a promising novel vaccine candidate for Equine Infectious Anemia.
• This approach offers potential protection against diverse American EIAV field strains.
• Further experimental validation is warranted to confirm efficacy and safety in vivo.